<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-10" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-10" data-turn-id-container="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-10" data-testid="conversation-turn-18" data-scroll-anchor="false" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="3a3746f7-f998-433a-8c3b-7f85de658a83" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<h2 data-section-id="erfnu9" data-start="0" data-end="43"><strong>Alcohol Use Disorder Market Insights</strong></h2>
<p data-start="45" data-end="765"><a href="https://www.delveinsight.com/report-store/alcohol-use-disorder-market"><strong>Alcohol Use Disorder (AUD)</strong></a> represents a major global public health challenge with growing demand for more effective and accessible treatment options. The US AUD market was valued at approximately USD 1.1 billion in 2025 and is projected to grow at a CAGR of 12.1% during 2026&ndash;2036. Market growth is being driven by rising awareness, expanding treatment-seeking populations, and increasing focus on targeted and personalized therapies. Although VIVITROL currently dominates the market, emerging therapies such as AD04 are expected to significantly reshape the future treatment landscape. Expanding regulatory approvals and reduced social stigma are also anticipated to improve treatment adoption over the forecast period.</p>
<h3 data-start="767" data-end="792"><strong data-start="767" data-end="792">Key Market Highlights</strong></h3>
<ul data-start="793" data-end="1046">
<li data-section-id="9dtiay" data-start="793" data-end="837">CAGR of 12.1% projected during 2026&ndash;2036</li>
<li data-section-id="6y68pq" data-start="838" data-end="888">US market size reached USD 1.1 billion in 2025</li>
<li data-section-id="7jeb0g" data-start="889" data-end="941">Rising demand for better-tolerated AUD therapies</li>
<li data-section-id="z3obh2" data-start="942" data-end="992">VIVITROL held the highest market share in 2025</li>
<li data-section-id="ojcp5r" data-start="993" data-end="1046">AD04 expected to emerge as a major future therapy</li>
</ul>
<h2 data-section-id="1tywbr1" data-start="1053" data-end="1102"><strong>Alcohol Use Disorder Epidemiology Insights</strong></h2>
<p data-start="1104" data-end="1822">Alcohol Use Disorder remains one of the most prevalent neuropsychiatric and substance use disorders worldwide. In 2025, 12-month diagnosed prevalent cases in the United States were estimated at approximately 25.6 million. Among severity-specific cases, mild AUD represented the largest patient segment, accounting for nearly 13 million cases in the US. Epidemiological patterns vary globally, with Japan reporting a higher proportion of severe AUD cases due to ALDH2 deficiency, while Europe has observed relatively stable or declining alcohol consumption trends among adolescents and young adults. Increasing awareness and improved diagnosis are expected to further expand the identified patient population over time.</p>
<h3 data-start="1824" data-end="1855"><strong data-start="1824" data-end="1855">Key Epidemiology Highlights</strong></h3>
<ul data-start="1856" data-end="2198">
<li data-section-id="1plfnx" data-start="1856" data-end="1929">12-month diagnosed prevalent AUD cases in the US reached 25.6 million</li>
<li data-section-id="15v29s5" data-start="1930" data-end="1990">Mild AUD accounted for approximately 13 million US cases</li>
<li data-section-id="vr572z" data-start="1991" data-end="2049">Japan reported a higher proportion of severe AUD cases</li>
<li data-section-id="14txjzr" data-start="2050" data-end="2126">Europe observed stable or declining drinking trends in youth populations</li>
<li data-section-id="1u1mi6k" data-start="2127" data-end="2198">Growing awareness expected to improve diagnosis and treatment rates</li>
</ul>
<h2 data-section-id="1hh80ra" data-start="2205" data-end="2264"><strong>Alcohol Use Disorder Pipeline and Emerging Therapies</strong></h2>
<p data-start="2266" data-end="3018">The <a href="https://www.delveinsight.com/report-store/alcohol-use-disorder-pipeline-insight"><strong>Alcohol Use Disorder pipeline</strong></a> is evolving rapidly with the exploration of novel neurological and metabolic targets aimed at improving treatment efficacy and patient adherence. Emerging therapies are focused on overcoming limitations associated with current treatments, including the requirement for prior abstinence and limited long-term effectiveness. Companies are investigating innovative mechanisms such as 5-HT3 antagonism, NOP receptor modulation, mGluR5 inhibition, and GLP-1-based approaches to provide more personalized and effective treatment options. AD04 remains one of the most promising investigational therapies, particularly due to its oral administration, genetically targeted approach, and potential to improve accessibility for patients with AUD.</p>
<h3 data-start="3020" data-end="3068"><strong data-start="3020" data-end="3068">Key Pipeline and Emerging Therapy Highlights</strong></h3>
<ul data-start="3069" data-end="3372">
<li data-section-id="s8fq5g" data-start="3069" data-end="3126">AD04 expected to become a major future therapy in AUD</li>
<li data-section-id="p6rayn" data-start="3127" data-end="3192">Increasing focus on genetically targeted treatment approaches</li>
<li data-section-id="una7qb" data-start="3193" data-end="3251">Novel neurological pathways under active investigation</li>
<li data-section-id="1pob67o" data-start="3252" data-end="3313">Oral therapies gaining preference for patient convenience</li>
<li data-section-id="d0jzx2" data-start="3314" data-end="3372">Expanding pipeline addressing high unmet clinical need</li>
</ul>
<h3 data-start="3374" data-end="3407"><strong data-start="3374" data-end="3407">Key Companies in the Pipeline</strong></h3>
<ul data-start="3408" data-end="3536" data-is-last-node="" data-is-only-node="">
<li data-section-id="1f2a1y5" data-start="3408" data-end="3433">Adial Pharmaceuticals</li>
<li data-section-id="d4xiif" data-start="3434" data-end="3453">Beckley Psytech</li>
<li data-section-id="155nf1w" data-start="3454" data-end="3476">Atai Life Sciences</li>
<li data-section-id="miyjw1" data-start="3477" data-end="3491">MediciNova</li>
<li data-section-id="kma3q0" data-start="3492" data-end="3507">Tempero Bio</li>
<li data-section-id="eoms33" data-start="3508" data-end="3524">Nxera Pharma</li>
<li data-section-id="d5e5ba" data-start="3525" data-end="3536" data-is-last-node="">Altimmune</li>
</ul>
</div>
</div>
</div>
</div>
<div class="mt-3 w-full empty:hidden">&nbsp;</div>
</div>
</div>
</section>
</div>
</div>

Alcohol Use Disorder Market

Alcohol Use Disorder Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.